MiNK Therapeutics, Inc. reported a net loss of $12.5 million for the fiscal year ending December 31, 2025, compared to a loss of $10.8 million in the previous year. The company's accumulated deficit has now reached $156.7 million. Research and development expenses decreased by 9% to $5.8 million, primarily due to reduced clinical trial costs and personnel expenses. In contrast, general and administrative expenses surged by 56% to $6.7 million, driven by increased professional fees and share-based compensation costs. The company’s cash and cash equivalents stood at $13.4 million at year-end, which management believes will be sufficient to meet liquidity requirements for over a year.
Strategically, MiNK is focused on advancing its lead product candidate, agenT-797, an allogeneic iNKT cell therapy, which has shown promise in treating various cancers and critical pulmonary immune failure. The company has treated nearly 100 patients with agenT-797, generating insights that support its development in both oncology and pulmonary diseases. A Phase 2 trial is currently underway to evaluate the therapy's efficacy in patients with severe pneumonia and acute respiratory failure. Additionally, MiNK is developing next-generation engineered iNKT programs, including MiNK-413 and MiNK-215, which are in preclinical stages.
Operationally, MiNK has maintained a small workforce, with 15 full-time employees as of February 2026, 33% of whom hold Ph.D. degrees. The company has relied on Agenus Inc. for various administrative and operational support services, which has raised concerns about the potential challenges of separating its resources from Agenus in the future. As of December 31, 2025, MiNK had a related party note of $5.2 million, which was fully repaid in January 2026.
Looking ahead, MiNK anticipates continued operating losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company is exploring various funding avenues, including strategic partnerships and collaborations, to support its liquidity needs. However, there remains substantial doubt about its ability to continue as a going concern, given the reliance on future funding and the inherent uncertainties in the biopharmaceutical industry.
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. develops allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its platform leverages native and engineered iNKT cells to target tumors, treat viral ARDS, and prevent graft-versus-host disease. The company focuses on scalable manufacturing, proprietary cell engineering, and strategic collaborations to deliver innovative immunotherapies with broad applicability and potential for rapid clinical impact.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.